ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Zhang Ningning

Provisional: name at one institution (moderate confidence)As of 10 November 2026

Known by name at one institution; no external author ID yet. Name as it appears in ClinicalTrials.gov.

Their work

Papers: 0
Trials: 2 (principal investigator on 2)
Grants: 0
Collaborators: 1

Papers, trials and grants by year

2026: 2 trials

Trials 2

FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Principal investigator NCT07845565 ↗
Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. Principal investigator NCT07854977 ↗

Closest collaborators

The 1 strongest of 1 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Hao Jihui · 2 shared trials, 2026
- Trial FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Metastatic Pancreatic… NCT07845565 ↗
- Trial Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metas… NCT07854977 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.